Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25870236 | 0.88 | CHRM2 (0.43) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL23825249 | 0.84 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL21274860 | 0.83 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL20973202 | 0.83 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL1991738 | 0.83 | CHRM2 (0.42) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL1988348 | 0.83 | CHRM2 (0.42) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL4484103 | 0.83 | KDM1A (0.38) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL21752540 | 0.83 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL27478921 | 0.82 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL24801818 | 0.81 | HSD17B10 (0.46) | CHRM2CHRM1CHRM3HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260085066-A1 | LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| WO-2024254490-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | ACRIVON THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-10-31 | — | — | US | disclosed |
| CN-111902141-A | Glucocerebroside binders for IKAROS degradation | C4医药公司 | 2020-11-06 | — | — | CN | disclosed |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| WO-2020098723-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | 上海轶诺药业有限公司 | 2020-05-22 | — | — | WO | disclosed |
| US-10308608-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10308608-B2 | Histone deacetylase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20180370915-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2018-12-27 | — | — | US | disclosed |
| WO-2017004522-A1 | HISTONE DEACETYLASE INHIBTORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | CHRM2 226/4885CHRM1 80/4885CHRM3 338/4885 |
| US-20190142834-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | CHRM2 4685/4885CHRM1 4622/4885CHRM3 4268/4885 |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CHRM2 3312/4885CHRM1 3462/4885CHRM3 3543/4885 |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | CHRM2 4822/4885CHRM1 4818/4885CHRM3 4820/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | CHRM2 2913/4885CHRM1 3154/4885CHRM3 3427/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | CHRM2 4394/4885CHRM1 4263/4885CHRM3 4638/4885 |
| US-10722514-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | USP7, SENP7, USP8 | CHRM2 4685/4885CHRM1 4622/4885CHRM3 4268/4885 |
| US-20180370915-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | CHRM2 4836/4885CHRM1 4856/4885CHRM3 4783/4885 |
| US-10308608-B2 | Histone deacetylase inhibitors | HDAC1, HDAC2, HDAC3 | CHRM2 4836/4885CHRM1 4856/4885CHRM3 4783/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | CHRM2 4309/4885CHRM1 4030/4885CHRM3 4248/4885 |
| US-20260085066-A1 | LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, PARK7, NEDD4 | CHRM2 3878/4885CHRM1 4088/4885CHRM3 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.